<DOC>
	<DOCNO>NCT01312961</DOCNO>
	<brief_summary>Primary Objective : Investigate effect SAR231893 ( REGN668 ) administer subcutaneously ( SC ) weekly 12 week compare placebo reduce incidence asthma exacerbation patient persistent moderate severe eosinophilic asthma . Secondary Objectives : Assess safety tolerability SAR231893 ( REGN668 ) administer SC weekly 12 week patient persistent moderate severe eosinophilic asthma . Assess SAR231893 ( REGN668 ) serum concentration follow weekly SC dose 12 week patient persistent moderate severe eosinophilic asthma .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability SAR231893 ( REGN668 ) Patients With Persistent Moderate Severe Eosinophilic Asthma</brief_title>
	<detailed_description>The total duration study period per patient 18-20 week break follow : - Screening period : 14 day , - Treatment period : 12 week , - Follow-up period : 6-8 week .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Pulmonary Eosinophilia</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>Inclusion criterion : Medical diagnosis persistent asthma least 12 month whose : airway inflammation likely eosinophilic , asthma partially control uncontrolled Inhaled Corticosteroid ( ICS ) plus LongActing Beta2 Agonist ( LABA ) therapy . On stable dose either Fluticasone/Salmeterol , Budesonide/Formoterol , Mometasone/Formoterol combination therapy least 1 month prior screen . Signed Informed Consent Form Health Insurance Portability Accountability Act ( HIPAA ) Authorization Form . Exclusion criterion : Less 18 year great 65 year age . Clinically relevant abnormal laboratory value suggest unknown disease require evaluation . Chronic obstructive pulmonary disease and/or lung diseases impair Pulmonary Function Tests . Betaadrenergic receptor blocker require reason . Current smoker cessation smoking within 6 month prior screen . Previous smoke smoke history &gt; 10 cigarette pack/years . Participation another study within 6 month prior screen study medication antibody within 30 day prior screen study medication . Known suspect noncompliance , alcohol drug abuse . Inability follow procedure study ( eg , due language problem , psychological disorder ) . Concomitant severe disease disease use ICS longacting beta2 agonist contraindicate . Known allergy doxycycline relate compound . Pregnancy intention become pregnant course study , breast feeding , unwillingness use highly effective method contraception throughout study woman childbearing potential . Recent history parasitic infection travel parasitic endemic area within 6 month prior screen . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>